

**Amendments to the Claims:**

This listing of the claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-24 (Canceled).

25 (Currently Amended). An isolated amino-terminally truncated RANTES polypeptide ~~comprising~~ consisting of residues 3-68 of a RANTES polypeptide according to SEQ ID NO:21, wherein the truncated RANTES polypeptide lacks NH<sub>2</sub>-terminal amino acid residues 1-2 and has ~~chemokine~~ CCR1 and CCR3 antagonistic activity and CCR5 agonistic activity.

26-27 (Canceled).

28 (Currently Amended). The isolated amino-terminally truncated RANTES of claims ~~24-27~~25, wherein the truncated RANTES polypeptide is in glycosylated form.

29 (Currently Amended). A pharmaceutical composition comprising an isolated truncated RANTES polypeptide according to ~~any one of claims 24-27~~25, wherein the composition comprises one or more pharmaceutically acceptable carriers and/or excipients.

30 (Previously Presented). The pharmaceutical composition according to claim 29, wherein the isolated truncated RANTES polypeptide is in glycosylated form.